Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine long-term outcomes in elderly cardiac surgery
NCT03289325Completed
- Sponsor
- Peking University First Hospital
- Start
- Oct 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of dexmedetomidine in coronary artery disease (CAD) and heart valve disease (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Overall Survival at 6 years. Started Oct 2021; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
coronary artery disease (CAD)heart valve disease
Beyond the preview
Go deeper on NCT03289325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03289325.